Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches

International Journal of Physiology, Pathophysiology and Pharmacology

Volumn 2, Issue 2, 2010, Pages 161-178

  Grasso, Simone ^a   Santi, Luca ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Nanodevice; Nanoparticle; Nanotechnology; Protein cage; Virus like particle; Virus particle

Indexed keywords

NANOPARTICLE; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRAL NANOPARTICLE;

ARTICLE; GENETIC ENGINEERING; IN VITRO STUDY; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICOCHEMICAL MODEL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; VIRUS MORPHOLOGY;

EID: 77954713640     PISSN: None     EISSN: 19448171     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Li L, Liu J, Diao Z, Shu D, Guo P and Shen G. Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells. Mol Biosyst 2009; 5: 1361-1368.
2. Yamashita I, Iwahori K and Kumagai S. Ferritin in the field of nanodevices. Biochim Biophys Acta 2010; doi:10.1016/j.bbagen.2010.03.005.
3. Flenniken ML, Liepold LO, Crowley BE, Willits DA, Young MJ and Douglas T. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun (Camb) 2005; 447-449.
4. Donini M, Lico C, Baschieri S, Conti S, Magliani W, Polonelli L and Benvenuto E. Production of an engineered killer peptide in Nicotiana benthamiana by using a potato virus X expression system. Appl Environ Microbiol 2005; 71: 6360-6367.
5. Cruz SS, Chapman S, Roberts AG, Roberts IM, Prior DA and Oparka KJ. Assembly and movement of a plant virus carrying a green fluorescent protein overcoat. Proc Natl Acad Sci USA 1996; 93: 6286-6290.
6. Strable E, Johnson JE and Finn MG. Natural Nanochemical Building Blocks: Icosahedral Virus Particles Organized by Attached Oligonucleotides. Nano Letters 2004; 4: 1385-1389.
7. Kaltgrad E, O'Reilly MK, Liao L, Han S, Paulson JC and Finn MG. On-virus construction of polyvalent glycan ligands for cell-surface receptors. J Am Chem Soc 2008; 130: 4578-4579.
8. Bar H, Yacoby I and Benhar I. Killing cancer cells by targeted drug-carrying phage nanomedicines. BMC Biotechnol 2008; 8: 37.
9. Miyanohara A, Imamura T, Araki M, Sugawara K, Ohtomo N and Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J Virol 1986; 59: 176-180.
10. Hirschman SZ, Price P, Garfinkel E, Christman J and Acs G. Expression of cloned hepatitis B virus DNA in human cell cultures. Proc Natl Acad Sci USA 1980; 77: 5507-5511.
11. Huang Z, Santi L, LePore K, Kilbourne J, Arntzen CJ and Mason HS. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 2006; 24: 2506-2513.
12. Standring DN, Ou JH, Masiarz FR and Rutter WJ. A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes. Proc Natl Acad Sci USA 1988; 85: 8405-8409.
13. Burrell CJ, Mackay P, Greenaway PJ, Hofschneider PH and Murray K. Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322. Nature 1979; 279: 43-47.
14. Hardy K, Stahl S and Kupper H. Production in B. subtilis of hepatitis B core antigen and a major antigen of foot and mouth disease virus. Nature 1981; 293: 481-483.
15. Schodel F, Milich DR and Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J Immunol 1990; 145: 4317-4321.
16. Koletzki D, Lundkvist A, Sjolander KB, Gelderblom HR, Niedrig M, Meisel H, Kruger DH and Ulrich R. Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. Virology 2000; 276: 364-375.
17. Kratz PA, Bottcher B and Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 1999; 96: 1915-1920.
18. Koletzki D, Biel SS, Meisel H, Nugel E, Gelderblom HR, Kruger DH and Ulrich R. HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein. Biol Chem 1999; 380: 325-333.
19. Bottcher B, Wynne SA and Crowther RA. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 1997; 386: 88-91.
20. Zlotnick A, Cheng N, Stahl SJ, Conway JF, Steven AC and Wingfield PT. Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: implications for morphogenesis and organization of encapsidated RNA. Proc Natl Acad Sci USA 1997; 94: 9556-9561.
21. Beterams G, Bottcher B and Nassal M. Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids. FEBS Lett 2000; 481: 169-176.
22. Montross L, Watkins S, Moreland RB, Mamon H, Caspar DL and Garcea RL. Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. J Virol 1991; 65: 4991-4998.
23. Abbing A, Blaschke UK, Grein S, Kretschmar M, Stark CM, Thies MJ, Walter J, Weigand M, Woith DC, Hess J and Reiser CO. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 2004; 279: 27410-27421.
24. Li QG, Lindman K and Wadell G. Hydropathic characteristics of adenovirus hexons. Arch Virol 1997; 142: 1307-1322.
25. Prasuhn DE, Jr., Singh P, Strable E, Brown S, Manchester M and Finn MG. Plasma clearance of bacteriophage Qbeta particles as a function of surface charge. J Am Chem Soc 2008; 130: 1328-1334.
26. Zhang Y, Yang M, Portney NG, Cui D, Budak G, Ozbay E, Ozkan M and Ozkan CS. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed Microdevices 2008; 10: 321-328.
27. Lico C, Capuano F, Renzone G, Donini M, Marusic C, Scaloni A, Benvenuto E and Baschieri S. Peptide display on Potato virus X: molecular features of the coat protein-fused peptide affecting cell-to-cell and phloem movement of chimeric virus particles. J Gen Virol 2006; 87: 3103-3112.
28. Bendahmane M, Koo M, Karrer E and Beachy RN. Display of epitopes on the surface of tobacco mosaic virus: impact of charge and isoelectric point of the epitope on virus-host interactions. J Mol Biol 1999; 290: 9-20.
29. Kazaks A, Borisova G, Cvetkova S, Kovalevska L, Ose V, Sominskaya I, Pumpens P, Skrastina D and Dislers A. Mosaic hepatitis B virus core particles presenting the complete preS sequence of the viral envelope on their surface. J Gen Virol 2004; 85: 2665-2670.
30. Brown SD, Fiedler JD and Finn MG. Assembly of hybrid bacteriophage Qbeta virus-like particles. Biochemistry 2009; 48: 11155-11157.
31. Hamamoto H, Sugiyama Y, Nakagawa N, Hashida E, Matsunaga Y, Takemoto S, Watanabe Y and Okada Y. A new tobacco mosaic virus vector and its use for the systemic production of angiotensin-I-converting enzyme inhibitor in transgenic tobacco and tomato. Biotechnology (N Y) 1993; 11: 930-932.
32. Sugiyama Y, Hamamoto H, Takemoto S, Watanabe Y and Okada Y. Systemic production of foreign peptides on the particle surface of tobacco mosaic virus. FEBS Lett 1995; 359: 247-250.
33. Borovsky D, Rabindran S, Dawson WO, Powell CA, Iannotti DA, Morris TJ, Shabanowitz J, Hunt DF, DeBondt HL and DeLoof A. Expression of Aedes trypsin-modulating oostatic factor on the virion of TMV: A potential larvicide. Proc Natl Acad Sci USA 2006; 103: 18963-18968.
34. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D and Ryan MD. Analysis of the aphtho176 virus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 2001; 82: 1013-1025.
35. de Felipe P and Izquierdo M. Construction and characterization of pentacistronic retrovirus vectors. J Gen Virol 2003; 84: 1281-1285.
36. Lewis JD, Destito G, Zijlstra A, Gonzalez MJ, Quigley JP, Manchester M and Stuhlmann H. Viral nanoparticles as tools for intravital vascular imaging. Nat Med 2006; 12: 354-360.
37. Chatterji A, Ochoa W, Shamieh L, Salakian SP, Wong SM, Clinton G, Ghosh P, Lin T and Johnson JE. Chemical conjugation of heterologous proteins on the surface of Cowpea mosaic virus. Bioconjug Chem 2004; 15: 807-813.
38. Smith ML, Lindbo JA, Dillard-Telm S, Brosio PM, Lasnik AB, McCormick AA, Nguyen LV and Palmer KE. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 2006; 348: 475-488.
39. Steinmetz NF, Mertens ME, Taurog RE, Johnson JE, Commandeur U, Fischer R and Manchester M. Potato virus X as a novel platform for potential biomedical applications. Nano Lett 2010; 10: 305-312.
40. Wang Q, Kaltgrad E, Lin T, Johnson JE and Finn MG. Natural supramolecular building blocks. Wild-type cowpea mosaic virus. Chem Biol 2002; 9: 805-811.
41. Wang Q, Chan TR, Hilgraf R, Fokin VV, Sharpless KB and Finn MG. Bioconjugation by copper(I)catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc 2003; 125: 3192-3193.
42. Sen Gupta S, Kuzelka J, Singh P, Lewis WG, Manchester M and Finn MG. Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug Chem 2005; 16: 1572-1579.
43. Steinmetz NF, Evans DJ and Lomonossoff GP. Chemical introduction of reactive thiols into a viral nanoscaffold: a method that avoids virus aggregation. Chembiochem 2007; 8: 1131-1136.
44. Peabody DS. A Viral Platform for Chemical Modification and Multivalent Display. J Nanobiotechnology 2003; 1: 5.
45. Hooker JM, Kovacs EW and Francis MB. Interior surface modification of bacteriophage MS2. J Am Chem Soc 2004; 126: 3718-3719.
46. Steinmetz NF, Lomonossoff GP and Evans DJ. Cowpea mosaic virus for material fabrication: addressable carboxylate groups on a programmable nanoscaffold. Langmuir 2006; 22: 3488-3490.
47. Steinmetz NF, Bize A, Findlay KC, Lomonossoff GP, Manchester M, Evans DJ and Prangishvili D. Site-specific and Spatially Controlled Addressability of a New Viral Nanobuilding Block: Sulfolobus islandicus Rod-shaped Virus 2. Adv Funct Mater 2008; 18: 3478-3486.
48. Ngweniform P, Abbineni G, Cao B and Mao C. Self-assembly of drug-loaded liposomes on genetically engineered target-recognizing M13 phage: a novel nanocarrier for targeted drug delivery. Small 2009; 5: 1963-1969.
49. Werner S, Marillonnet S, Hause G, Klimyuk V and Gleba Y. Immunoabsorbent nanoparticles based on a tobamovirus displaying protein A. Proc Natl Acad Sci USA 2006; 103: 17678-17683.
50. Gleiter S and Lilie H. Coupling of antibodies via protein Z on modified polyoma virus-like particles. Protein Sci 2001; 10: 434-444.
51. Schmidt U, Gunther C, Rudolph R and Bohm G. Protein and peptide delivery via engineered polyomavirus-like particles. FASEB J 2001; 15: 1646-1648.
52. Goldmann C, Stolte N, Nisslein T, Hunsmann G, Luke W and Petry H. Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus. J Virol Methods 2000; 90: 85-90.
53. Ren Y, Wong SM and Lim LY. In vitroreassembled plant virus-like particles for loading of polyacids. J Gen Virol 2006; 87: 2749-2754.
54. McCarthy MP, White WI, Palmer-Hill F, Koenig S and Suzich JA. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol 1998; 72: 32-41.
55. Touze A and Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998; 26: 1317-1323.
56. Douglas T and Young M. Host-guest encapsulation of materials by assembled virus protein cages. Nature 1998; 393: 152-155.
57. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ and Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-180.
58. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.
59. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W and Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.
60. Temming K, Schiffelers RM, Molema G and Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005; 8: 381-402.
61. Van Bockstaele F, Holz JB and Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 2009; 10: 1212-1224.
62. Shadidi M and Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 2003; 6: 363-371.
63. Singh P, Destito G, Schneemann A and Manchester M. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology 2006; 4: 2.
64. Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MK, VandenDriessche T, Fukuda H, Kondo A, Ueda M, Seno M, Tanizawa K and Kuroda S. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol 2003; 21: 885-890.
65. Mammen M, Choi S-K and Whitesides GM. Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. Angewandte Chemie International Edition 1998; 37: 2754-2794.
66. Kaiser CR, Flenniken ML, Gillitzer E, Harmsen AL, Harmsen AG, Jutila MA, Douglas T and Young MJ. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int J Nanomedicine 2007; 2: 715-733.
67. Rae CS, Khor IW, Wang Q, Destito G, Gonzalez MJ, Singh P, Thomas DM, Estrada MN, Powell E, Finn MG and Manchester M. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 2005; 343: 224-235.
68. Singh P, Prasuhn D, Yeh RM, Destito G, Rae CS, Osborn K, Finn MG and Manchester M. Biodistribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release 2007; 120: 41-50.
69. Jennings GT and Bachmann MF. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med 2007; 7: 143-155.
70. Jennings GT and Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009; 49: 303-326.
71. Storni T and Bachmann MF. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J Immunol 2004; 172: 6129-6135.
72. Kurts C, Robinson BW and Knolle PA. Crosspriming in health and disease. Nat Rev Immunol 2010; 10: 403-414.
73. Malyala P, O'Hagan DT and Singh M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev 2009; 61: 218-225.
74. Chikh G, de Jong SD, Sekirov L, Raney SG, Kazem M, Wilson KD, Cullis PR, Dutz JP and Tam YK. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol 2009; 21: 757-767.
75. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA and Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172: 1777-1785.
76. Santi L, Huang Z and Mason H. Virus-like particles production in green plants. Methods 2006; 40: 66-76.
77. Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, Goodwin P, Arntzen CJ and Mason HS. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci USA 2005; 102: 3378-3382.
78. Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q and Mason HS. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008; 26: 1846-1854.
79. Baum A and Garcia-Sastre A. Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 2010; 38: 1283-1299.
80. Lico C, Mancini C, Italiani P, Betti C, Boraschi D, Benvenuto E and Baschieri S. Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. Vaccine 2009; 27: 5069-5076.
81. McCormick AA, Corbo TA, Wykoff-Clary S, Nguyen LV, Smith ML, Palmer KE and Pogue GP. TMVpeptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models. Vaccine 2006; 24: 6414-6423.
82. Brown WL, Mastico RA, Wu M, Heal KG, Adams CJ, Murray JB, Simpson JC, Lord JM, TaylorRobinson AW and Stockley PG. RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 2002; 45: 371-380.
83. van Beusechem VW, Grill J, Mastenbroek DC, Wickham TJ, Roelvink PW, Haisma HJ, Lamfers ML, Dirven CM, Pinedo HM and Gerritsen WR. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol 2002; 76: 2753-2762.
84. Wu M, Sherwin T, Brown WL and Stockley PG. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine 2005; 1: 67-76.
85. Destito G, Yeh R, Rae CS, Finn MG and Manchester M. Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol 2007; 14: 1152-1162.
86. Dirven CM, Grill J, Lamfers ML, Van der Valk P, Leonhart AM, Van Beusechem VW, Haisma HJ, Pinedo HM, Curiel DT, Vandertop WP and Gerrit178 sen WR. Gene therapy for meningioma: improved gene delivery with targeted adenoviruses. J Neurosurg 2002; 97: 441-449.
87. Gomme PT, McCann KB and Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005; 10: 267-273.
88. Ren Y, Wong SM and Lim LY. Folic acidconjugated protein cages of a plant virus: a novel delivery platform for doxorubicin. Bioconjug Chem 2007; 18: 836-843.
89. Allen M, Bulte JW, Liepold L, Basu G, Zywicke HA, Frank JA, Young M and Douglas T. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med 2005; 54: 807-812.
90. Anderson EA, Isaacman S, Peabody DS, Wang EY, Canary JW and Kirshenbaum K. Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the MS2 capsid. Nano Lett 2006; 6: 1160-1164.
91. Loo L, Guenther RH, Basnayake VR, Lommel SA and Franzen S. Controlled encapsidation of gold nanoparticles by a viral protein shell. J Am Chem Soc 2006; 128: 4502-4503.
92. Kay MA, Holterman AX, Meuse L, Gown A, Ochs HD, Linsley PS and Wilson CB. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191-197.
93. Lieber A, Vrancken Peeters MJ, Meuse L, Fausto N, Perkins J and Kay MA. Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retrovirus transduction of hepatocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 6210-6214.
94. Mizuno M, Yoshida J, Colosi P and Kurtzman G. Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res 1998; 89: 76-80.
95. Nguyen DM, Spitz FR, Yen N, Cristiano RJ and Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirusmediated p53 gene transfer. J Thorac Cardiovasc Surg 1996; 112: 1372-1376; discussion 1376-1377.
96. Specthrie L, Bullitt E, Horiuchi K, Model P, Russel M and Makowski L. Construction of a microphage variant of filamentous bacteriophage. J Mol Biol 1992; 228: 720-724.
97. Wei B, Wei Y, Zhang K, Wang J, Xu R, Zhan S, Lin G, Wang W, Liu M, Wang L, Zhang R and Li J. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed Pharmacother 2009; 63: 313-318. Int J Physiol Pathophysiol Pharmacol 2010;2(2):161-178